secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2026-06-11T20:05:35+00:00
Accession:  0001104659-26-072931
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio shareholders approve 3.5M share equity plan increase, elect three directors
--------------------------------------------------------------------------------

- Stockholders approved 3,500,000 share increase to 2019 Equity Incentive Plan; total authorized shares now 10,932,620.
- Joseph Capper, Betty Jo Rocchio, and William Plovanic elected as Class I directors until 2029.
- KPMG LLP ratified as independent auditor for fiscal 2026 with 33.4M votes for, 17,890 against.
- Non-binding advisory vote on named executive officer compensation passed: 20.9M for, 6.9M against.
- Plan amendment prohibits repricing of options/SARs without stockholder approval and extends plan term to 10 years from April 8, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926072931/0001104659-26-072931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926072931/tm2617369d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-072931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer